RM 1929

Drug Profile

RM 1929

Alternative Names: RM1929

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator Aspyrian Therapeutics
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Head and neck cancer
  • Preclinical Cancer

Most Recent Events

  • 11 May 2017 Interim adverse events and efficacy data from a phase I trial in head and neck cancer released by Aspyrian Therapeutics
  • 27 Apr 2017 Aspyrian Therapeutics plans registration trials for Head and neck cancer in early 2018
  • 27 Apr 2017 Aspyrian Therapeutics plans proof-of-concept phase II trials for Cancer in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top